Trial · NCT07897292
The Efficacy of Exosomes Combined With Synthetic Bone Graft for the Treatment of Periodontal Intra-bony Defects
NCT07897292, Early phase 1, Not yet recruiting, Khoshoe Al-mokhtar Mohammed
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Efficacy of Exosomes Combined With Synthetic Bone Graft for the Treatment of Periodontal Intra-bony Defects. Trials, record NCT07897292. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07897292
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Efficacy of Exosomes Combined With Synthetic Bone Graft for the Treatment of Periodontal Intra-bony Defects
- NCT number
- NCT07897292
- Status
- Not yet recruiting
- Phases
- Early phase 1
- Enrollment
- 30 participants, estimated
- Lead sponsor
- Khoshoe Al-mokhtar Mohammed
- Conditions
- Intra-Bony Defects in Periodontitis Patients
- Interventions
- single flap approach, single flap approach combined with nanocrystalline hydroxyapatite bone substitute, Exosomes
- First posted
- 2026-10-27
- Last updated
- 2026-10-27
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | clinical attachment level (CAL) gain using UNC-15 periodontal probe (University of North Carolina periodontal probe) | baseline, 3, 6, and 9 months after treatment | change in attachment level in mm using UNC-15 periodontal probe (University of North Carolina periodontal probe) |
| Primary | Marginal bone level (MBL) | baseline, 3, 6, and 9 months after treatment | change in marginal bone level (MBL) using Cone beam C.T (CBCT) |
| Secondary | Gingival index (GI) | baseline, 3, 6, and 9 months after treatment | change in gingival inflammation. The degree of gingival inflammation will be recorded as follow: * 0 = Normal gingiva. * 1 = Mild inflammation, slight change in color, slight edema and no bleeding on probing. * 2 = Moderate inflammation, redness, edema and bleeding on probing. 33 Patients and methods * 3= Severe inflammation, marked redness, edema and tendency to spontaneous bleeding. |
| Secondary | Modified plaque index (MPI) | baseline, 3, 6, and 9 months after treatment | plaque accumulation around the gingival margin. The degree of plaque accumulation will be recorded as follow: * 0= No plaque around the gingival margin. * 1= A thin film of plaque around the gingival margin. The plaque may be recognized only by running a probe across the tooth surface. * 2= Moderate accumulation of soft deposits on the gingival margin and/or adjacent tooth surface, which can be seen by the naked eye. * 3= Abundance plaque accumulation within the gingival pocket and/or on the gingival margin and adjacent tooth surface and hard deposits on the tooth surface are seen. |
| Secondary | Probing depth (PD) using UNC-15 periodontal probe (University of North Carolina periodontal probe) | baseline, 3, 6, and 9 months after treatment | change in pocket depth in mm using UNC-15 periodontal probe (University of North Carolina periodontal probe) |
| Secondary | level of BMP-2 | baseline, 1, 4 and 12 weeks after surgery | Evaluation of the level of BMP-2 in Gingival crevicular fluid (GCF) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07897292
GET https://conductscience.org/api/trials/v1/NCT07897292/registered